Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-3641 ragweed SLIT tablet in children with ragweed-induced rhinoconjunctivitis
2014-004341-27Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2015
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial in allergic rhinoconjunctivitis (ARC) comparing MK-3641 with Placebo (2 arms). Primary endpoint: Total Combined Score during peak ragweed season. Started Sep 2015; status: completed.
02
Drugs
ambrosia artemisiifolia allergen extract
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on 2014-004341-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004341-27.